Stay updated on Emricasan in NASH Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Emricasan in NASH Fibrosis Clinical Trial page.

Latest updates to the Emricasan in NASH Fibrosis Clinical Trial page
- CheckyesterdayChange DetectedThe study page now displays a 403 Forbidden error instead of the full study record, indicating restricted access to the page and showing a minimal header with a Home link.SummaryDifference17%

- Check8 days agoChange DetectedRevision: v3.7.0 was added to the page, replacing the previous Revision: v3.6.6. This signals a new site version deployment rather than changes to the study details, eligibility criteria, or results.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6, signaling a minor update to the page’s underlying template or CMS. This change does not affect the study details, content, or user-facing functionality.SummaryDifference0.0%

- Check43 days agoChange DetectedRevision label on the page updated from v3.6.4 to v3.6.5. This signifies a minor build/content update and does not change the study information presented.SummaryDifference0.0%

- Check57 days agoChange DetectedFooter revision label updated from v3.6.3 to v3.6.4, indicating a small update to the page's versioning. It does not modify any study data or displayed content.SummaryDifference0.0%

- Check72 days agoChange DetectedSteatotic Liver Disease has been added and Fatty Liver Disease removed from the page's keyword taxonomy, reflecting updated naming conventions for liver conditions and affecting how the study is indexed and discovered.SummaryDifference0.1%

Stay in the know with updates to Emricasan in NASH Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Emricasan in NASH Fibrosis Clinical Trial page.